X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Robert Zirkelbach

Robert Zirkelbach Robert Zirkelbach is a former Executive Vice President of Public Affairs at PhRMA.

Recent Posts

"If Washington isn’t careful, we might leave innovation behind"

By Robert Zirkelbach  |    June 24, 2019
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, a Voters for Cures advocate from...   Read More

Survey: AARP members support sharing medicine discounts with seniors

By Robert Zirkelbach  |    June 12, 2019
Earlier this year, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) released a proposed rule to reform the rebate system in Medicare Part D. In our current system,...   Read More

Giving patients a voice: PhRMA launches Voters for Cures to support the next generation of treatments and cures

By Robert Zirkelbach  |    April 25, 2019
When we launched the GOBOLDLY campaign two years ago, we set out to spotlight the new era of medicine and the tremendous opportunity that exists to tackle our most complex and devastating health...   Read More

The PBM story you haven’t heard: Hidden fees quadrupled in two years

By Robert Zirkelbach  |    March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...   Read More

Americans want to know more than just the list price of a medicine—and we’re answering their call

By Robert Zirkelbach  |    October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...   Read More

How much are hospitals marking up the price of medicines? The answer may surprise you.

By Robert Zirkelbach  |    October 17, 2017
Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of America...   Read More

PhRMA response to Washington Post and 60 Minutes stories

By Robert Zirkelbach  |    October 16, 2017
The opioid epidemic confronting America is a growing public health crisis from which none of us are immune. Its impact is felt by families across the country, in small towns and large cities, coast...   Read More

New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs

By Robert Zirkelbach  |    July 12, 2017
Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the...   Read More

Fighting multiple sclerosis: New Together ad illuminates the journey of patient & scientist

By Robert Zirkelbach  |    May 31, 2017
Meet Laurel and Ian. Laurel is a patient living with multiple sclerosis (MS), and Ian is a scientist developing new treatments to help Laurel and the other 2.3 million people with MS live longer,...   Read More

A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements

By Robert Zirkelbach  |    May 15, 2017
Today, we released the latest chapter of GOBOLDLY™ advertising titled New World, featuring the extraordinary breakthroughs in science being discovered by biopharmaceutical researchers.   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates